WASHINGTON - Biotech drug maker Tercica is expected to learn this week whether U.S. health regulators will approve a treatment for a rare growth disorder that it has licensed. The Food and Drug Administration is scheduled to make a decision Thursday on Somatuline Autogel, an injectable drug to treat acromegaly, a hormone disorder that can cause the hands, feet, noise and mouth to grow unusually large.
